On December 12, 2022, Novozymes and Chr. Hansen announced that they have entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies.
On March 30, 2023, Novozymes’ and Chr. Hansen’s shareholders approved the combination to create a leading global biosolutions partner. The completion of the proposed merger is subject to customary merger control and other regulatory approvals from relevant authorities.
Please see below for documents and other relevant information regarding the proposed merger.